Last week Senator McCaskill (D-Mo) stopped by the JDRF office in Crestwood to receive thanks for her work on the Artificial Pancreas Project.
The Artificial Pancreas is an external device which people with T1D could use to do what their bodies cannot, control both high and low blood sugar around the clock. It works by combining a continuous glucose monitor (CGM) and an insulin pump with sophisticated computer software to provide automatically the right amount of insulin at the right time.
In 2006, the FDA added artificial pancreas technology to its Critical Path list, making a commitment to advance these systems. Last December they announced that the draft guidance, or first stage, was compete.
"It appears that the draft guidance lays out a rapid timetable to move from inpatient trials to outpatient trials to prove the AP's safety and efficacy” said Jeffrey Brewer, President and CEO of JDRF, in December.
JDRF invited Senator McCaskill to celebrate the apparently continued funding of the AP project.















Comments